Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico

Documenti analoghi

• Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study
  di: Martin Haluzík, et al.
  Pubblicazione: (2025)
• Long‐term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli‐durability 24‐month observational study
  di: Rayaz A. Malik, et al.
  Pubblicazione: (2025)
• Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
  di: Jochen Seufert, et al.
  Pubblicazione: (2024)
• Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials
  di: Wenying Yang, et al.
  Pubblicazione: (2024)
• Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes
  di: Juan P. Frías, et al.
  Pubblicazione: (2025)